Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BioMerieux launches heart failure diagnosis and prognosis aid

BioMerieux launches heart failure diagnosis and prognosis aid

2nd October 2007

BioMerieux yesterday announced the launch of VIDAS NT-proBNP, a test that aids the diagnosis and prognosis of heart failure, following the completion of a licensing deal struck with Roche Diagnostics.

The test is a quantitative marker of heart stress that provides diagnostic information that allows the distinction of heart failure from a range of other conditions with similar symptoms such as pulmonary embolism or lung disorders, asserts the company.

Stephane Bancel, chief executive of bioMerieux, commented: "The unique VIDAS design makes this assay available 24-hours-a-day for emergency departments.

"Year to date, bioMerieux has now launched its 3rd VIDAS test that brings high medical value to clinicians," he added.

VIDAS NT-proBNP has the potential to identify the early stages of heart failure in the absence of clinically-obvious symptoms, according to bioMerieux.

Last month, the firm announced the presentation of a new handbook on sepsis at an international forum on the syndrome.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.